Thymocyte selection‐associated high mobility box protein regulates T lymphocytes exhaustion in patients with myelodysplastic syndromes by inhibiting PI3K/AKT/mTOR pathway
Hematological Oncology · 2024
DOI: 10.1002/hon.3224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2024. Verfasst von Haiyue Niu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Myelodysplastic Syndromes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Beijing Cancer Prevention &Treatment Society, General project funded by Tianjin Municipal Education Commission, The Zhao Yicheng Medical Science Foundation of Tianjin China.
Themen: Mobilisation
Abstract (Originalsprache)
Myelodysplastic syndromes (MDS) patients often experience CD8 + T lymphocytes exhaustion, which plays a crucial role in the development of MDS. However, the specific role of thymocyte selection‐associated high mobility box protein (TOX) in the CD8 + T lymphocytes exhaustion in MDS patients remains unclear. In this study, we investigated the role of TOX in CD8 + T lymphocytes exhaustion in patients with MDS. The expression of TOX, inhibitory receptors (IRs), and functional molecules in peripheral blood T lymphocytes of MDS patients and normal controls were detected using flow cytometry. Lentiviral transduction was used to create stable TOX‐knockdown CD8 + T lymphocytes, and small interfering RNA (si‐RNA) was used to knock down TOX in Jurkat cells. The expression of TOX was found to be significantly higher in CD8 + T lymphocytes of MDS patients compared to normal controls. This was associated with upregulated IRs and reduced expression of functional molecules such as Granzyme and Perforin. Myelodysplastic syndromes patients with higher TOX expression had poor clinical indicators and shorter survival. Knockdown of TOX using sh‐RNA partially reverses the exhausted phenotype and enhances the lethality of CD8 + T lymphocytes. Moreover, the knockdown of TOX using si‐RNA in Jurkat cells improved cell proliferation activity, down‐regulated IRs and activated PI3K/AKT/mTOR signaling pathway. TOX promotes the exhaustion of CD8 + T lymphocytes by inhibiting PI3K/AKT/mTOR pathway, and targeted inhibition of TOX could partially restore the effector functions and activity of CD8 + T lymphocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
ORCID-Profile: Haiyue Niu, Huaquan Wang
Förderung
- Beijing Cancer Prevention &Treatment Society
- General project funded by Tianjin Municipal Education Commission
- The Zhao Yicheng Medical Science Foundation of Tianjin China
- The National Natural Science Foundation of China
- Scientific research project funded by Tianjin Association of Medical and Health
- Key Technology Research and Development Program of Tianjin China
- Tianjin Key Medical Discipline Construction Project
Zitieren
APA
Niu, H., Zhang, M., Liu, M., Yang, L., Yang, L., Ren, J., Yu, Y., Liu, Y., Xing, L., Shao, Z., & Wang, H. (2024). Thymocyte selection‐associated high mobility box protein regulates T lymphocytes exhaustion in patients with myelodysplastic syndromes by inhibiting PI3K/AKT/mTOR pathway. Hematological Oncology. https://doi.org/10.1002/hon.3224
Vancouver
Niu H, Zhang M, Liu M, Yang L, Yang L, Ren J, et al. Thymocyte selection‐associated high mobility box protein regulates T lymphocytes exhaustion in patients with myelodysplastic syndromes by inhibiting PI3K/AKT/mTOR pathway. Hematological Oncology. 2024. doi:10.1002/hon.3224
BibTeX
@article{Niu2024,
author = {Niu, Haiyue and Zhang, Mengying and Liu, Mengyuan and Yang, Liyan and Yang, Liping and Ren, Jie and Yu, Yating and Liu, Yumei and Xing, Limin and Shao, Zonghong and Wang, Huaquan},
title = {Thymocyte selection‐associated high mobility box protein regulates T lymphocytes exhaustion in patients with myelodysplastic syndromes by inhibiting PI3K/AKT/mTOR pathway},
journal = {Hematological Oncology},
year = {2024},
doi = {10.1002/hon.3224}
}
EUVIMED